Table 1 Prevalence (%) (95% confidence interval) in the nondiabetic population* of the Metabolic Syndrome, according to NCEP ATP III.
| Â | Age group | Â | |||
|---|---|---|---|---|---|
| Â | 25 - 34 | 35 - 44 | 45 - 54 | 55 - 64 | Overall prevalence |
Barquisimeto | Â | Â | Â | Â | Â |
   Men | 19.7 (13.1-26.2) | 27.2 (20.7-33.7) | 32.4 (25.5-39.4) | 38.1 (30.7-45.5) | 23.0 (19.1-27.0) |
   Women | 11.6 (7.2-16.0) | 23.9 (19.2-28.6) | 37.7 (32.3-43.1) | 47.8 (41.8-53.8) | 22.7 (20.0-25.3) |
Bogota | Â | Â | Â | Â | Â |
   Men | 10.7 (6.2-15.1) | 18.5 (13.1-23.8) | 25.9 (20.4-31.4) | 30.1 (22.9-37.3) | 14.7 (11.8-17.5) |
   Women | 8.3 (4.6-11.9) | 16.8 (10.8-22.7) | 36.2 (30.2-42.3) | 48.6 (41.8-55.5) | 18.2 (15.5-20.9) |
Buenos Aires | Â | Â | Â | Â | Â |
   Men | 11.8 (7.2-16.4) | 21.8 (15.7-27.9) | 26.6 (20.3-32.9) | 33.0 (26.0-40.0) | 17.3 (14.8-19.8) |
   Women | 3.3 (0.8-5.9) | 7.5 (3.6-11.4) | 16.9 (10.4-23.5) | 24.6 (17.8-31.4) | 9.7 (7.1-12.3) |
Lima | Â | Â | Â | Â | Â |
   Men | 10.0 (5.9-14.2) | 15.8 (9.0-22.5) | 19.8 (14.1-25.4) | 25.1 (18.2-32.1) | 13.2 (10.6-15.8) |
   Women | 6.4 (3.2- 9.7) | 18.7 (12.9-24.4) | 34.8 (28.8-40.7) | 36.8 (29.5-44.0) | 17.6 (15.0-20.1) |
Mexico City | Â | Â | Â | Â | Â |
   Men | 22.2 (15.6-28.8) | 22.6 (17.7-27.6) | 33.5 (28.0-39.0) | 37.2 (30.6-43.7) | 22.4 (18.9-25.8) |
   Women | 16.5 (11.9-21.1) | 27.4 (20.3-34.5) | 35.5 (30.0-40.9) | 49.3 (42.4-56.1) | 22.2 (19.1-25.4) |
Quito | Â | Â | Â | Â | Â |
   Men | 3.6 (0.7- 6.5) | 6.3 (3.5- 9.1) | 12.9 (8.2-17.6) | 13.4 (8.6-18.2) | 5.5 (3.9-7.1) |
   Women | 7.8 (3.6-12.1) | 18.0 (11.8-24.2) | 35.5 (29.3-41.6) | 37.4 (31.1-43.7) | 16.4 (13.5-19.3) |
Santiago | Â | Â | Â | Â | Â |
   Men | 9.9 (5.8-14.0) | 17.5 (12.0-23.0) | 27.0 (20.8-33.1) | 31.5 (25.5-37.4) | 15.3 (12.8-17.9) |
   Women | 11.6 (7.3-15.9) | 22.3 (16.0-28.6) | 26.1 (20.4-31.7) | 42.4 (36.4-48.5) | 19.0 (16.0-22.0) |